Participated · Series A · Feb 2026

Avisi Technologies, Inc. is a clinical-stage company focused on creating novel ophthalmic solutions, most notably VisiPlate®, an investigational aqueous shunt engineered from an ultrathin, patented metamaterial designed to maintain intra-ocular pressure through multiple microchannels that resist blockage and scarring. The device targets the unmet need for long-term, low-maintenance glaucoma care and is currently being evaluated in the FDA IDE-approved SAPPHIRE pivotal trial that is enrolling patients across the United States. Avisi’s broader pipeline includes V-001, a sustained intraocular drug-delivery platform, and VisiPlate-S, a drainage device intended for use during cataract surgery. Proceeds from its latest financing will fund the SAPPHIRE trial and advance additional pipeline programs addressing the full spectrum of glaucomatous disease. The company has garnered recognition and non-dilutive support from the National Science Foundation, the Glaucoma Research Foundation, Johnson & Johnson JLABS, and other industry accelerators. Current investors include both venture funds and angel networks, underscoring diversified backing for its development roadmap. No revenue or user figures have been disclosed to date.

Led · Series A · Jan 2026

Spiro Medical is a venture-backed medical device company based in Irvine, California that is building the first purpose-built Pulmonary Neuromodulation System (PNM) for asthma patients. The proprietary implant targets neural reflex pathways in the lungs with the goal of reducing symptoms such as wheezing, shortness of breath, and coughing. Founded by Stephen Pyles, M.D., Kurt Gehlsen, M.D., Ph.D., Rinda Sama, and G. Jay Jiang, Ph.D., the company enters the market with issued patents and initial human data supporting the technology’s clinical potential. Proceeds from its recent financing will fund final system design, clinical trials, and U.S. regulatory work. Leadership claims deep expertise in implantable neuromodulation, positioning the team to build a “world-class” product. Although the company is pre-revenue, it is targeting a large addressable market of more than 28 million U.S. asthma sufferers and 300 million patients worldwide.

Participated · Series B · May 2025

PAQ Therapeutics is a biotechnology company focused on leveraging targeted protein degradation to suppress oncogenic KRAS signaling in cancer. Its lead candidates include PT0253, a KRAS G12D degrader, and PT0511, a pan-KRAS degrader designed to address multiple oncogenic KRAS variants. The company has initiated a first-in-human, open-label Phase 1 trial of PT0511 to evaluate safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with KRAS-altered solid tumors. Proceeds from recent financing will also support the ongoing Phase 1 development of PT0253. PAQ’s platform aspires to achieve deep, selective tumor suppression while maintaining favorable safety and combinability profiles, potentially overcoming limitations of current KRAS or pan-RAS inhibitor therapies. The firm’s total Series B capital now stands at $77 million, providing a strengthened balance sheet to advance multiple clinical programs.

Participated · Series A · Jan 2024

ZWI Therapeutics develops protein therapeutics using a proprietary, patented polymer called polycarboxybetaine to create protein‑polymer conjugates intended as alternatives to PEG‑conjugated drugs. In preclinical animal models, its polycarboxybetaine conjugates have shown consistently low or no immunogenicity and improved pharmacokinetics versus PEG conjugates, which the company expects will translate to enhanced clinical durability and safety. The platform is also applicable to nanoparticles and hydrogels, with hydrogels highlighted for cellular therapy use. ZWI’s lead candidate, ZWI‑001 (an uricase‑polycarboxybetaine conjugate), has demonstrated preclinical proof of concept for treating hyperuricemia in severe gout and the company is progressing toward filing an IND after receiving FDA INTERACT guidance on CMC, nonclinical, and clinical plans. ZWI intends to out‑license its technology to pharmaceutical partners for specific development programs. The company announced board additions and a new CEO concurrent with the financing.

Participated · Series B · Sep 2023

Grit Biotechnology is a Shanghai-based cell therapy company founded in 2019 focused on developing transformative tumor-infiltrating lymphocyte (TIL) cancer treatments. Its pipeline includes GT101, described as the fastest-developing TIL therapy in China, which is slated to enter a pivotal Phase II trial by the end of 2023. The company also advances gene-edited TIL products and operates four core technology platforms central to TIL development: StemTexp®, StaViral®, KOReTIL® and ImmuT Finder®, a genome-wide CRISPR/Cas9 screening platform. GT201, a genetically engineered TIL, has an IND approved by the CFDA and has entered Phase I clinical trials. GT316 leverages ImmuT Finder®-identified targets, shows tumor elimination in PDX models with low-dose IL-2 and is in investigator-initiated trials in China. Grit plans to use new funding to support its TIL pipeline, including the pivotal Phase II for GT101 and advancement of its gene-edited TIL programs.